Franziska Olm
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Franziska Olm has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Sandra Lindstedt
Department of Clinical Sciences, Lund University, Lund, Sweden
15 shared publications - Gabriel Hirdman
Department of Cardiothoracic Surgery and Transplantation, Skåne University Hospital, Lund, Sweden
9 shared publications - Snejana Hyllén
Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden
8 shared publications Dag Edström
Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden
6 shared publicationsMargareta Mittendorfer
Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden; Department of Clinical Sciences, Lund University, Lund, Sweden; Lund Stem Cell Centre, Lund University, Lund, Sweden
6 shared publicationsAnna Niroomand
Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden; Department of Clinical Sciences, Lund University, Lund, Sweden; Lund Stem Cell Centre, Lund University, Lund, Sweden
5 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
Cell and Gene Therapy in Lung Transplantation: From Experimental Promise towards Clinical Translation
- 28 October 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
Open AccessCell and Gene Therapy in Lung Transplantation: From Experimental Promise towards Clinical Translation
- Open Access
Cell therapy for regeneration of injured donor lungs for transplantation
Donor organ shortage remains the major barrier to transplantation resulting in deaths on the waiting list. For lungs, aspiration-related injury is a common cause of donor organ discard and increases the risk of primary graft dysfunction. Currently, no effective therapies exist to repair damaged donor lungs prior to transplantation. Here, we investigated whether mesenchymal stromal cells (MSCs) from bone marrow or full-term amniotic fluid could restore severely injured donor lungs in a porcine model integrating ex vivo lung perfusion, transplantation and post-transplant follow-up (n=48; 24 donors, 24 recipients). MSCs were administered either once during ex vivo lung perfusion or repeatedly across lung perfusion and the early post-transplant period and compared with placebo treated controls. A single dose conferred only partial benefit, whereas repeated dosing restored graft function, normalized gas exchange and haemodynamics, and prevented graft dysfunction. MSCs from both sources were similarly effective in repeated regimens. These findings identify dosing schedule, rather than cell source, as key determinant of durable organ rescue and support perfusion-guided cell therapy as potentially generalizable regenerative strategy across solid-organ transplantation.
Open AccessCell therapy for regeneration of injured donor lungs for transplantation
Donor organ shortage remains the major barrier to transplantation resulting in deaths on the waiting list. For lungs, aspiration-related injury is a common cause of donor organ discard and increases the risk of primary graft dysfunction. Currently, no effective therapies exist to repair damaged donor lungs prior to transplantation. Here, we investigated whether mesenchymal stromal cells (MSCs) from bone marrow or full-term amniotic fluid could restore severely injured donor lungs in a porcine model integrating ex vivo lung perfusion, transplantation and post-transplant follow-up (n=48; 24 donors, 24 recipients). MSCs were administered either once during ex vivo lung perfusion or repeatedly across lung perfusion and the early post-transplant period and compared with placebo treated controls. A single dose conferred only partial benefit, whereas repeated dosing restored graft function, normalized gas exchange and haemodynamics, and prevented graft dysfunction. MSCs from both sources were similarly effective in repeated regimens. These findings identify dosing schedule, rather than cell source, as key determinant of durable organ rescue and support perfusion-guided cell therapy as potentially generalizable regenerative strategy across solid-organ transplantation.
- Open Access
- 14 November 2025
- Published by Springer Nature in Research Square
Mitochondrial Therapy During Machine Perfusion Restores the Function of DCD Livers: A Cross-Circulation Evaluation for Transplant Suitability
Donation after circulatory death (DCD) has significantly increased the number of organs potentially available for transplantation. Livers are more vulnerable than most other solid organs to warm ischemia in the DCD process. The injury induced by warm ischemic time (WIT) is further exacerbated during cold ischemia and reperfusion, resulting in tissue damage caused by the production of reactive oxygen species. These are not only cytotoxic but also perpetuate mitochondrial dysfunction and cell death. To improve the utilization of livers from uncontrolled DCD (uDCD) or controlled DCD (cDCD) donors with prolonged WIT, new strategies to mitigate WIT must be developed.Ex vivo normothermic machine perfusion (NMP) has increased DCD organ utilization and improved the assessment of the viability of organs before transplantation. NMP could also serve as a platform for isolated treatment of organs prior to transplant. An innovative approach to mitigate organ injury is to treat damaged livers with mitochondrial transplantation (MTx). In this study, we tested the efficacy of xenogeneic mitochondrial administration to restore the function of porcine DCD livers with two hours of warm ischemia. DCD livers were explanted and connected to NMP, where mitochondrial transplantation was administered as a bolus dose in the portal vein and hepatic artery at the start of perfusion. After four hours of NMP, treated livers demonstrated a significant increase in bile production, improved bile quality, and restored cytoarchitecture.To further assess the transplantation suitability of these livers post-NMP, they were connected to cross-circulation (CC) with a recipient pig. After six hours of CC, untreated livers became oedematous, exhibited significant aspartate aminotransferase elevations in the bile, and showed cellular degeneration, including near-complete loss of Kupffer cells. In contrast, livers treated with MTx maintained function across CC and were comparable to healthy controls. These data validate the efficacy of MTx in restoring function in DCD livers exposed to prolonged ischaemic times, presenting a promising approach to expand the donor pool.
- 14 November 2025
- Published by Springer Nature in Research Square
Open AccessMitochondrial Therapy During Machine Perfusion Restores the Function of DCD Livers: A Cross-Circulation Evaluation for Transplant Suitability
Donation after circulatory death (DCD) has significantly increased the number of organs potentially available for transplantation. Livers are more vulnerable than most other solid organs to warm ischemia in the DCD process. The injury induced by warm ischemic time (WIT) is further exacerbated during cold ischemia and reperfusion, resulting in tissue damage caused by the production of reactive oxygen species. These are not only cytotoxic but also perpetuate mitochondrial dysfunction and cell death. To improve the utilization of livers from uncontrolled DCD (uDCD) or controlled DCD (cDCD) donors with prolonged WIT, new strategies to mitigate WIT must be developed.Ex vivo normothermic machine perfusion (NMP) has increased DCD organ utilization and improved the assessment of the viability of organs before transplantation. NMP could also serve as a platform for isolated treatment of organs prior to transplant. An innovative approach to mitigate organ injury is to treat damaged livers with mitochondrial transplantation (MTx). In this study, we tested the efficacy of xenogeneic mitochondrial administration to restore the function of porcine DCD livers with two hours of warm ischemia. DCD livers were explanted and connected to NMP, where mitochondrial transplantation was administered as a bolus dose in the portal vein and hepatic artery at the start of perfusion. After four hours of NMP, treated livers demonstrated a significant increase in bile production, improved bile quality, and restored cytoarchitecture.To further assess the transplantation suitability of these livers post-NMP, they were connected to cross-circulation (CC) with a recipient pig. After six hours of CC, untreated livers became oedematous, exhibited significant aspartate aminotransferase elevations in the bile, and showed cellular degeneration, including near-complete loss of Kupffer cells. In contrast, livers treated with MTx maintained function across CC and were comparable to healthy controls. These data validate the efficacy of MTx in restoring function in DCD livers exposed to prolonged ischaemic times, presenting a promising approach to expand the donor pool.
- Open Access
- 23 May 2025
- Published by Frontiers Media SA in Frontiers in Transplantation
- Vol. 4, 1516728
Exhaled breath particles as a diagnostic tool for bronchiolitis obliterans syndrome in lung transplant recipients: a longitudinal study
Background: Long-term survival after lung transplantation is significantly shorter compared with other solid organ transplantations. Chronic lung allograft dysfunction (CLAD), including bronchiolitis obliterans syndrome (BOS), remains the major barrier to survival. CLAD is diagnosed according to ISHLT's guidelines: a 20% drop in FEV1 using spirometry for CLAD grade 1. Given the difficulties of confounders using spirometry, other methods for precise diagnostics are being explored. Exhaled breath particles (EBP) measured as particle flow rate (PFR) from the airways have been explored as a potential method to diagnose lung injury in preclinical and clinical settings of acute respiratory distress syndrome (ARDS) and primary graft dysfunction (PGD). In fact, PFR has been shown to indicate early signs of lung injury in both ARDS and PGD settings. In the present study, we explored whether PFR could be used as a marker for BOS.Methods: Lung transplant patients with different BOS grades were included. All patients were in stable condition without ongoing infections and >2 years posttransplantation. PFR (in particles per liter) was measured using a Particles in Exhaled Air (PExA) 2.0 device (PExA, Gothenburg, Sweden), containing an optical particle counter, at the start of the study and then 1 year out, in total two time points (0 and 1 year). Particles in the diameter range of 0.41–4.55 µm were measured.Results: At both the start of the study and 1 year out, patients with BOS grade 0 had significantly higher PFR than patients with BOS grades 2–3. During the study period, patients who progressed in their BOS grade all expressed lower PFR as they progressed in BOS grade, while patients who remained stable in BOS grade did not. The particle distribution between the different BOS grades had a similar pattern; however, it significantly decreased PFR with severity in the BOS grade.Conclusions: EBP expressed as PFR could be used to distinguish severity in BOS grade and could be used to follow the progression of BOS over time. PFR could be used as a new diagnostic tool for BOS and to follow the development of lung function over time.
- 23 May 2025
- Published by Frontiers Media SA in Frontiers in Transplantation
- Vol. 4, 1516728
Open AccessExhaled breath particles as a diagnostic tool for bronchiolitis obliterans syndrome in lung transplant recipients: a longitudinal study
Background: Long-term survival after lung transplantation is significantly shorter compared with other solid organ transplantations. Chronic lung allograft dysfunction (CLAD), including bronchiolitis obliterans syndrome (BOS), remains the major barrier to survival. CLAD is diagnosed according to ISHLT's guidelines: a 20% drop in FEV1 using spirometry for CLAD grade 1. Given the difficulties of confounders using spirometry, other methods for precise diagnostics are being explored. Exhaled breath particles (EBP) measured as particle flow rate (PFR) from the airways have been explored as a potential method to diagnose lung injury in preclinical and clinical settings of acute respiratory distress syndrome (ARDS) and primary graft dysfunction (PGD). In fact, PFR has been shown to indicate early signs of lung injury in both ARDS and PGD settings. In the present study, we explored whether PFR could be used as a marker for BOS.Methods: Lung transplant patients with different BOS grades were included. All patients were in stable condition without ongoing infections and >2 years posttransplantation. PFR (in particles per liter) was measured using a Particles in Exhaled Air (PExA) 2.0 device (PExA, Gothenburg, Sweden), containing an optical particle counter, at the start of the study and then 1 year out, in total two time points (0 and 1 year). Particles in the diameter range of 0.41–4.55 µm were measured.Results: At both the start of the study and 1 year out, patients with BOS grade 0 had significantly higher PFR than patients with BOS grades 2–3. During the study period, patients who progressed in their BOS grade all expressed lower PFR as they progressed in BOS grade, while patients who remained stable in BOS grade did not. The particle distribution between the different BOS grades had a similar pattern; however, it significantly decreased PFR with severity in the BOS grade.Conclusions: EBP expressed as PFR could be used to distinguish severity in BOS grade and could be used to follow the progression of BOS over time. PFR could be used as a new diagnostic tool for BOS and to follow the development of lung function over time.
- Open Access
- 19 December 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (12) , 2893
Overlapping Systemic Proteins in COVID-19 and Lung Fibrosis Associated with Tissue Remodeling and Inflammation
Background/Objectives: A novel patient group with chronic pulmonary fibrosis is emerging post COVID-19. To identify patients at risk of developing post-COVID-19 lung fibrosis, we here aimed to identify systemic proteins that overlap with fibrotic markers identified in patients with idiopathic pulmonary fibrosis (IPF) and may predict COVID-19-induced lung fibrosis. Methods: Ninety-two proteins were measured in plasma samples from hospitalized patients with moderate and severe COVID-19 in Sweden, before the introduction of the vaccination program, as well as from healthy individuals. These measurements were conducted using proximity extension assay (PEA) technology with a panel including inflammatory and remodeling proteins. Histopathological alterations were evaluated in explanted lung tissue. Results: Connecting to IPF pathology, several proteins including decorin (DCN), tumor necrosis factor receptor superfamily member 12A (TNFRSF12A) and chemokine (C-X-C motif) ligand 13 (CXCL13) were elevated in COVID-19 patients compared to healthy subjects. Moreover, we found incrementing expression of monocyte chemotactic protein-3 (MCP-3) and hepatocyte growth factor (HGF) when comparing moderate to severe COVID-19. Conclusions: Both extracellular matrix- and inflammation-associated proteins were identified as overlapping with pulmonary fibrosis, where we found DCN, TNFRSF12A, CXCL13, CXCL9, MCP-3 and HGF to be of particular interest to follow up on for the prediction of disease severity.
- 19 December 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (12) , 2893
Open AccessOverlapping Systemic Proteins in COVID-19 and Lung Fibrosis Associated with Tissue Remodeling and Inflammation
Background/Objectives: A novel patient group with chronic pulmonary fibrosis is emerging post COVID-19. To identify patients at risk of developing post-COVID-19 lung fibrosis, we here aimed to identify systemic proteins that overlap with fibrotic markers identified in patients with idiopathic pulmonary fibrosis (IPF) and may predict COVID-19-induced lung fibrosis. Methods: Ninety-two proteins were measured in plasma samples from hospitalized patients with moderate and severe COVID-19 in Sweden, before the introduction of the vaccination program, as well as from healthy individuals. These measurements were conducted using proximity extension assay (PEA) technology with a panel including inflammatory and remodeling proteins. Histopathological alterations were evaluated in explanted lung tissue. Results: Connecting to IPF pathology, several proteins including decorin (DCN), tumor necrosis factor receptor superfamily member 12A (TNFRSF12A) and chemokine (C-X-C motif) ligand 13 (CXCL13) were elevated in COVID-19 patients compared to healthy subjects. Moreover, we found incrementing expression of monocyte chemotactic protein-3 (MCP-3) and hepatocyte growth factor (HGF) when comparing moderate to severe COVID-19. Conclusions: Both extracellular matrix- and inflammation-associated proteins were identified as overlapping with pulmonary fibrosis, where we found DCN, TNFRSF12A, CXCL13, CXCL9, MCP-3 and HGF to be of particular interest to follow up on for the prediction of disease severity.
- Open Access
- 12 November 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (3) , 448-459
Xenotransplantation of mitochondria: A novel strategy to alleviate ischemia-reperfusion injury during ex vivo lung perfusion
- 12 November 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (3) , 448-459
Open AccessXenotransplantation of mitochondria: A novel strategy to alleviate ischemia-reperfusion injury during ex vivo lung perfusion
- Open Access
- 24 August 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (12) , 2018-2030
Amniotic fluid-derived mesenchymal stem cells reduce inflammation and improve lung function following transplantation in a porcine model
- 24 August 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (12) , 2018-2030
Open AccessAmniotic fluid-derived mesenchymal stem cells reduce inflammation and improve lung function following transplantation in a porcine model
- Open Access
- 20 July 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (12) , 1919-1929
Restoring discarded porcine lungs by ex vivo removal of neutrophil extracellular traps
- 20 July 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (12) , 1919-1929
Open AccessRestoring discarded porcine lungs by ex vivo removal of neutrophil extracellular traps
- Open Access
- 20 February 2024
- Published by MDPI AG in Applied Sciences
- Vol. 14 (5) , 1726
Xylene versus Isopropanol for Paraffin Wax Processing of Lung Tissue
The microscopic observation of lung tissue is challenging due to its fragile nature. Xylene and isopropanol are common tissue-clearing reagents used before paraffin embedding, yet no studies have compared these two reagents in lung tissue processing. Due to the well-known health risks xylene could introduce to operators, as well as its environmental hazards, it has long been desired that a less harmful alternative to xylene with the same staining effects be introduced. Thus, we systematically assessed the efficacy of isopropanol as a substitution for xylene. Lung tissue obtained from diseased donors and explanted lungs from recipients were processed simultaneously using either xylene or isopropanol prior to paraffin embedding. Scoring of the overall staining quality after H&E staining, along with the ease of sectioning, was compared systematically. Fluorescent staining was performed to explore alveolar morphology and the overall lectin fluorescence signal between groups. To understand differences in antibody staining, the signal-to-noise ratio (SNR) of smooth muscle actin (SMA) and elastin was examined. No difference was observed with regard to ease of sectioning, staining quality, alveolar circularity, alveolar wall thickness or the SNR between slides processed with xylene or isopropanol. This study demonstrated comparable outcomes of isopropanol and xylene in lung tissue processing, suggesting isopropanol as a more favorable, operator- and environment-friendly substitute for xylene with regards to tissue processing.
- 20 February 2024
- Published by MDPI AG in Applied Sciences
- Vol. 14 (5) , 1726
Open AccessXylene versus Isopropanol for Paraffin Wax Processing of Lung Tissue
The microscopic observation of lung tissue is challenging due to its fragile nature. Xylene and isopropanol are common tissue-clearing reagents used before paraffin embedding, yet no studies have compared these two reagents in lung tissue processing. Due to the well-known health risks xylene could introduce to operators, as well as its environmental hazards, it has long been desired that a less harmful alternative to xylene with the same staining effects be introduced. Thus, we systematically assessed the efficacy of isopropanol as a substitution for xylene. Lung tissue obtained from diseased donors and explanted lungs from recipients were processed simultaneously using either xylene or isopropanol prior to paraffin embedding. Scoring of the overall staining quality after H&E staining, along with the ease of sectioning, was compared systematically. Fluorescent staining was performed to explore alveolar morphology and the overall lectin fluorescence signal between groups. To understand differences in antibody staining, the signal-to-noise ratio (SNR) of smooth muscle actin (SMA) and elastin was examined. No difference was observed with regard to ease of sectioning, staining quality, alveolar circularity, alveolar wall thickness or the SNR between slides processed with xylene or isopropanol. This study demonstrated comparable outcomes of isopropanol and xylene in lung tissue processing, suggesting isopropanol as a more favorable, operator- and environment-friendly substitute for xylene with regards to tissue processing.
- Open Access
- 13 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Publisher Correction: Targeting Toll-like receptor-driven systemic inflammation by engineering an innate structural fold into drugs
- 13 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Open AccessPublisher Correction: Targeting Toll-like receptor-driven systemic inflammation by engineering an innate structural fold into drugs